Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $42.60

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $42.60.

Several brokerages have commented on COLL. HC Wainwright increased their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. CWA Asset Management Group LLC acquired a new position in Collegium Pharmaceutical during the third quarter worth $434,000. Easterly Investment Partners LLC lifted its holdings in Collegium Pharmaceutical by 31.7% in the third quarter. Easterly Investment Partners LLC now owns 56,158 shares of the specialty pharmaceutical company’s stock valued at $2,170,000 after acquiring an additional 13,529 shares during the period. Principal Financial Group Inc. boosted its position in shares of Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in shares of Collegium Pharmaceutical by 265.9% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 114,965 shares of the specialty pharmaceutical company’s stock worth $4,442,000 after purchasing an additional 83,548 shares during the period. Finally, Emerald Advisers LLC increased its holdings in shares of Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after purchasing an additional 177,129 shares in the last quarter.

Collegium Pharmaceutical Trading Down 2.0 %

Shares of NASDAQ:COLL opened at $33.46 on Wednesday. The company has a market cap of $1.08 billion, a PE ratio of 12.97 and a beta of 0.94. The company’s 50 day moving average is $37.56 and its two-hundred day moving average is $35.28. Collegium Pharmaceutical has a 52 week low of $21.40 and a 52 week high of $42.29. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same period last year, the firm earned $1.13 earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 7.2% on a year-over-year basis. Equities analysts predict that Collegium Pharmaceutical will post 5.81 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.